YolTech Therapeutics - Olean Times Herald

Press Releases

YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia

YolTech Therapeutics

April 28, 2025

SHANGHAI , April 28, 2025 /PRNewswire/ -- YolTech Therapeutics Co.,Ltd, a clinical-stage in vivo gene editing company committed to pioneering the next...

Press Releases

YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)

YolTech Therapeutics

February 25, 2025

SHANGHAI , Feb. 25, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage in vivo gene editing company committed to pioneering the next generati...

Press Releases

YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia

YolTech Therapeutics

January 21, 2025

SHANGHAI , Jan. 20, 2025 /PRNewswire/ --YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced ...

Press Releases

YolTech Therapeutics Granted FDA Orphan Drug and Rare Pediatric Disease Designations for YOLT-203 to Treat Primary Hyperoxaluria Type 1

YolTech Therapeutics

December 27, 2024

SHANGHAI , Sept. 4, 2024 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage in vivo gene editing company, announced that the U.S. Food and Drug Ad...

Press Releases

YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR

YolTech Therapeutics

December 21, 2024

SHANGHAI , Dec. 21, 2024 /PRNewswire/ -- YolTech Therapeutics today announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201, a ...

Olean Times Herald

Get in touch with Olean Times Herald

Submit Content

Advertise

Subscribe